抑制肺上皮间质转化的抗纤维化药物研究进展  

Research progress of anti-fibrotic drugs that inhibit epithelial-mesenchymal transition in pulmonary fibrosis

作　　者：张丽冰 赵娜[1] 农骐郢 Zhang Libing;Zhao Na;Nong Qiying(Department of Occupational Medical Laboratory of Guangdong Province Hospital For Occupational Disease Prevention And Treatment,Guangzhou 510300,China;Acute Infectious Disease Control Department of Zengcheng Dstrict Center For Disease Control And Prevention,Guangzhou,511399,China)

机构地区：[1]广东省职业病防治院职业医学检验科,广州510300 [2]广州市增城区疾病预防控制中心急性传染病防治科,广州511399

出　　处：《中华劳动卫生职业病杂志》2023年第1期72-77,共6页Chinese Journal of Industrial Hygiene and Occupational Diseases

基　　金：国家自然科学基金(81903269);广东省自然科学基金(2021A1515012205,2021A 1515010081,2021A1515011546);广州市科技计划项目(202102080005);广东省医学科研基金项目(A2021228,A2022013);广东省职业病防治院级重点科研项目(Z2022-12)。

摘　　要：肺纤维化为肺部疾病的终末期病理性改变,严重影响人体的呼吸功能。国内外研究表明,上皮间质转化(EMT)是肺纤维化发展过程中重要的中间阶段,定向调控EMT上下游多条作用路径,如转化生长因子-1的经典Smads通路、非Smads通路等,可有效遏制EMT进程,缓解肺纤维化病变。本文对以EMT为作用靶点,改善肺纤维化病理作用机制的主要研究成果进行综述,为进一步研发抗肺纤维化药物提供理论基础和研究方向。Pulmonary fibrosis is the end-stage pathological change of lung diseases,which seriously affects the respiratory function of human body.A large number of studies at home and abroad have confirmed that epithelial-mesenchymal transition(EMT)is an important intermediate stage in the development of pulmonary fibrosis.Inhibition of multiple pathways upstream and downstream of EMT,such as the classical Smads pathway and non-Smads pathway of TGF-1 can effectively inhibit the process of EMT and alleviate pulmonary fibrosis.This article will review the main conclusions of the mechanism of action of EMT as a target to improve the pathology of pulmonary fibrosis so far,and provide a theoretical basis and research direction for further research and development of anti-pulmonary fibrosis drugs.

关 键 词：肺纤维化 上皮间质转化 转化生长因子 

分 类 号：R563[医药卫生—呼吸系统]